Experts and Doctors on neoplasm metastasis in Detroit, Michigan, United States


Locale: Detroit, Michigan, United States
Topic: neoplasm metastasis

Top Publications

  1. Borin T, Arbab A, Gelaleti G, Ferreira L, Moschetta M, Jardim Perassi B, et al. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. J Pineal Res. 2016;60:3-15 pubmed publisher
    ..When Y27632 was used, the effects were similar to those found with melatonin treatment. ..
  2. Menon S, Beningo K. Cancer cell invasion is enhanced by applied mechanical stimulation. PLoS ONE. 2011;6:e17277 pubmed publisher
    ..We further propose that in vivo, non-cancerous cells located within the tumor micro-environment may be capable of providing the necessary mechanical stimulus during the remodeling of the extracellular matrix surrounding the tumor. ..
  3. Krishnamoorthy S, Honn K. Eicosanoids in tumor progression and metastasis. Subcell Biochem. 2008;49:145-68 pubmed publisher
    ..This review summarizes some of the key aspects of eicasonoids and the associated enzymes, and the pathways they mediate in promoting tumor progression and metastasis. ..
  4. Nangia Makker P, Balan V, Raz A. Galectin-3 binding and metastasis. Methods Mol Biol. 2012;878:251-66 pubmed publisher
    ..Cancer Res 46: 5270-5275, 1986). In this chapter we describe the methods of purification of galectin-3 from transformed Escherichia coli and some of the commonly used functional assays for analyzing galectin-3 binding. ..
  5. Yang H, Wang Y, Cheryan V, Wu W, Cui C, Polin L, et al. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS ONE. 2012;7:e41214 pubmed publisher
    ..Together our in vitro and in vivo studies suggest that WA suppresses MPM growth by targeting multiple pathways that include blockage of proteasome activity and stimulation of apoptosis, and thus holds promise as an anti-MPM agent. ..
  6. Heath E, Bible K, Martell R, Adelman D, LoRusso P. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs. 2008;26:59-65 pubmed
    ..The data suggest that oral administration of SNS-032 may be feasible, though the tolerability and bioavailability of the oral formulation would have to be formally assessed. ..
  7. LoRusso P, Piha Paul S, Mita M, Colevas A, Malhi V, Colburn D, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol. 2013;71:193-202 pubmed publisher
    ..Overall, there appears to be a low potential for DDIs when vismodegib is co-administered with other medications. ..
  8. LoRusso P, Adjei A, Varterasian M, Gadgeel S, Reid J, Mitchell D, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-93 pubmed
    ..CI-1040 was well tolerated at 800 mg BID administered with food. Both target suppression and antitumor activity were demonstrated in this phase I study. ..
  9. Wojtukiewicz M, Hempel D, Sierko E, Tucker S, Honn K. Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis. Cancer Metastasis Rev. 2016;35:213-33 pubmed publisher
    ..Though a great deal is known regarding the role of thrombin in cancer dissemination, there are new data for multiple thrombin-mediated events that justify devoting focus to this topic with a comprehensive approach. ..

More Information


  1. Yu J, Ustach C, Kim H. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003;36:49-59 pubmed
  2. Fulton A, Hanchin C, Butler W. Heterogeneity of prostaglandin E2 binding in murine mammary tumor cells differing in metastatic potential. Invasion Metastasis. 1988;8:17-30 pubmed
    ..3H-PGE binding to line 410 cells is comparatively nonspecific as PGD2 is nearly as effective as PGE1, PGE2 and an analogue of PGE2 in competing with 3H-PGE2 and PGA2 also inhibits 3H-PGE2 binding. ..
  3. Nie D, Nemeth J, Qiao Y, Zacharek A, Li L, Hanna K, et al. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis. 2003;20:657-63 pubmed
    ..Taken together, our data suggest that an increase in 12-LOX expression enhances the metastatic potential of human prostate cancer cells. ..
  4. Cher M, Biliran H, Bhagat S, Meng Y, Che M, Lockett J, et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A. 2003;100:7847-52 pubmed
  5. Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012;31:455-67 pubmed publisher
    ..Due to the close relationship of EMT to cancer metastasis and chemoresistance, targeting EMT or reversing EMT is likely to lead to novel therapeutic approaches for the treatment of human cancers. ..
  6. Chen Y, Duniec Z, Liu B, Hagmann W, Gao X, Shimoji K, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res. 1994;54:1574-9 pubmed
  7. Zhang H, Meng F, Wu S, Kreike B, Sethi S, Chen W, et al. Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling. Cancer Res. 2011;71:4846-56 pubmed publisher
  8. Block J, Meng F, Wu G. Reversing cancer stemness. Aging (Albany NY). 2015;7:893-4 pubmed
  9. Diab M, Gabali A, Kittaneh M. Malignant acrospiroma: a case report in the era of next generation sequencing. BMC Cancer. 2017;17:221 pubmed publisher
    ..Genomic testing was also done using next generation sequencing. To the best of our knowledge, this is the first case of acral malignant acrospiroma with reported next generation sequencing results. ..
  10. Thakur C, Lu Y, Sun J, Yu M, Chen B, Chen F. Increased expression of mdig predicts poorer survival of the breast cancer patients. Gene. 2014;535:218-24 pubmed publisher
    ..Taken together, these data suggest that an increased expression of mdig is an important prognostic factor for poorer survival time of the breast cancer patients. ..
  11. Seward S, Semaan A, Qazi A, Gruzdyn O, Chamala S, Bryant C, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Lett. 2013;336:53-60 pubmed publisher
    ..Further, silencing of EZH2 resulted in re-expression of p21(waf1/cip1) and down-regulation of mutant p53. Finally, EZH2 knockdown contributed to attenuated EOC growth in SCID mice. ..
  12. Raz A, Pazerini G, Carmi P. Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein. Cancer Res. 1989;49:3489-93 pubmed
    ..Enzymatic treatment with collagenase confirmed the presence of a collagen-like structure in the polypeptide. Unexpectedly, the entire sequence is greater than 85% homologous to a rat low affinity IgE-binding protein. ..
  13. Singh R, Diwan A, Zhang P, Prieto V. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. J Cutan Pathol. 2007;34:220-5 pubmed
    ..There was no statistical difference in PI3 kinase expression in benign and malignant melanocytic lesions (p=0.2). PI3K is not overexpressed in melanocytic lesions. ..
  14. Downey C, Craig D, Basson M. Pressure activates colon cancer cell adhesion via paxillin phosphorylation, Crk, Cas, and Rac1. Cell Mol Life Sci. 2008;65:1446-57 pubmed publisher
    ..Thus, paxillin phosphorylation at tyrosines 31 and 118 together is necessary for pressure-induced adhesion. Paxillin, Crk and Cas form a trimeric complex that activates Rac1 and mediates this effect. ..
  15. Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu F, et al. Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011;71:1292-301 pubmed publisher
  16. Chinni S, Yamamoto H, Dong Z, Sabbota A, Bonfil R, Cher M. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446-57 pubmed publisher
    ..This transactivation contributes to enhanced invasive signals and metastatic growth in the bone microenvironment. ..
  17. Sheng S. The promise and challenge toward the clinical application of maspin in cancer. Front Biosci. 2004;9:2733-45 pubmed
    ..Specifically, this review discusses several likely molecular mechanisms underlying (1) the differential regulation of maspin expression, and (2) the biological activities of maspin in tumor progression. ..
  18. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, Raz A. Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. J Biol Chem. 2005;280:10419-26 pubmed
    ..The process by which phosphorylation modulates the enzymatic activity of PGI thus has an important implication for the understanding of the biological regulation of this key glucose metabolism-regulating enzyme. ..
  19. Podgorski I, Linebaugh B, Sameni M, Jedeszko C, Bhagat S, Cher M, et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia. 2005;7:207-23 pubmed
    ..Our results suggest that tumor-stromal interactions in the context of the bone microenvironment can modulate the expression of the cysteine protease cathepsin B. ..
  20. Yin S, Li X, Meng Y, Finley R, Sakr W, Yang H, et al. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem. 2005;280:34985-96 pubmed
  21. Pecot C, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013;4:2427 pubmed publisher
    ..The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent. ..
  22. Kamson D, Mittal S, Buth A, Muzik O, Kupsky W, Robinette N, et al. Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison. Mol Imaging. 2013;12:327-37 pubmed
    ..This approach may be particularly useful in patients with a newly diagnosed solitary ring-enhancing mass. ..
  23. Bonfil R, Dong Z, Trindade Filho J, Sabbota A, Osenkowski P, Nabha S, et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol. 2007;170:2100-11 pubmed
    ..Our findings are consistent with the hypothesis that prostate cancer-associated MT1-MMP plays a direct and/or indirect role in bone matrix degradation, thus favoring intraosseous tumor expansion. ..
  24. Funasaka T, Hu H, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J Biol Chem. 2007;282:36362-9 pubmed
  25. Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol. 2012;878:121-35 pubmed publisher
    ..If properly used, gelatin zymography is an excellent tool for the study of gelatinases in biological systems. ..
  26. Reeves D, Liu C. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2009;64:11-25 pubmed publisher
    ..Future research will better define the sequencing of therapies, as well as, explore the activity of novel combination regimens. ..
  27. Barnabas N, Xu L, Savera A, Hou Z, Barrack E. Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene. Prostate. 2011;71:857-71 pubmed publisher
    ..Copy number gain of the MIR151 gene and/or loss of the NKX3-1 gene in the primary tumor may indicate the presence of metastatic disease. ..
  28. Cho J, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, et al. The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP. J Biol Chem. 2008;283:17391-405 pubmed publisher
    ..Together, these results suggest a novel role for the 44-kDa form of MT1-MMP generated during autocatalytic processing in maintaining the pool of active enzyme at the cell surface. ..
  29. Gartner E, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933-7 pubmed publisher
    ..Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary. Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients. ..
  30. Meng F, Zhang H, Liu G, Kreike B, Chen W, Sethi S, et al. p38? mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. Neoplasia. 2011;13:472-82 pubmed
  31. Sarkar F, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009;64:489-500 pubmed